Source comparison
Melanotan-1 vs Melanotan-2: Structural and Functional Comparison
Receptor Selectivity Highly selective for MC1R Non-selective: binds MC1R, MC3R, MC4R, MC5R Melanotan-1 produces pigmentation with minimal off-target effects; melanotan-2's broader activity drives appetite and arousal changes FDA Approval Status Approved for er
This comparison does not assign a generated winner or score.
- Receptor Selectivity
- Highly selective for MC1R
- Non-selective: binds MC1R, MC3R, MC4R, MC5R
- Melanotan-1 produces pigmentation with minimal off-target effects; melanotan-2's broader activity drives appetite and arousal changes
- FDA Approval Status
- Approved for erythropoietic protoporphyria (EPP) under brand name Scenesse
- Not approved for any indication
- Melanotan-1 has regulatory clearance in specific rare disease contexts; melanotan-2 remains research-only
- Structural Difference
- Linear 13-amino-acid sequence
- Cyclic 7-amino-acid structure with lactam bridge
- The cyclic structure of melanotan-2 confers greater enzymatic stability but also enables binding to multiple receptor subtypes
- Observed Side Effects
- Nausea (10–15% in clinical trials), injection site reactions
- Nausea, flushing, spontaneous erections, appetite suppression, darkening of existing moles
- Melanotan-2's side effect profile reflects its non-selective receptor activity; effects beyond skin are common
- Half-Life
- Approximately 30–40 minutes subcutaneous
- 30–60 minutes, but receptor occupancy persists longer
- Both degrade relatively quickly, but melanocortin receptor binding outlasts plasma concentration
- Dosing Frequency (research models)
- Daily during loading phase, then maintenance dosing
- Variable: 0.25–2mg depending on study design and endpoint
- Melanotan-1 requires consistent dosing; melanotan-2 effects accumulate, allowing less frequent administration in some protocols
- Melanotan-1, marketed as afamelanotide (Melanotan 1), received FDA approval in 2019 exclusively for increasing pain-free light exposure in adult patients with erythropoietic protoporphyria. A rare genetic disorder causing severe photosensitivity. This approval validates the melanocortin pathway as a viable target for photoprotection, though afamelanotide's use remains restricted to this single indication under a risk evaluation and mitigation strategy (REMS) program due to theoretical concerns about melanoma promotion in predisposed individuals.
- Melanotan-2 diverged from this regulatory path due to its broader receptor profile. The same multi-target activity that makes it valuable in metabolic and neuroendocrine research also introduces complexity for therapeutic development. Clinical trials in the early 2000s exploring melanotan-2 for erectile dysfunction were terminated not because of safety signals, but because bremelanotide (which eliminated the pigmentation effect) offered a cleaner pharmacological profile for that specific application.
- Researchers choose between melanotan-1 and melanotan-2 based on study design: if the question concerns pure melanogenesis or photoprotection mechanisms, melanotan-1's MC1R selectivity provides clearer signal. If the research involves metabolic pathways, appetite regulation, or central melanocortin effects, melanotan-2's activity at MC3R and MC4R becomes the advantage. We've supplied both compounds to laboratories studying melanocortin biology, and the choice consistently maps to whether receptor selectivity or breadth is the experimental priority.